New Zealand

4 Vaccines Approved for Use in New Zealand

Protein Subunit

Novavax

Nuvaxovid

Approved in 37 countries
16 trials in 12 countries
Approval Source: ir.novavax.com
RNA

Pfizer/BioNTech

Comirnaty

Approved in 146 countries
84 trials in 27 countries
Approval Source: medsafe.govt.nz
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
64 trials in 31 countries
Approval Source: reuters.com

7 in Clinical Trials in New Zealand

Protein Subunit

Jiangsu Rec-Biotechnology Co Ltd

ReCOV

6 trials in 1 country
Protein Subunit

SK Bioscience Co Ltd

GBP510

6 trials in 6 countries
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 140 countries
64 trials in 31 countries
Inactivated

Valneva

VLA2001

Approved in 3 countries
6 trials in 3 countries
Inactivated

Valneva

VLA2101

Protein Subunit

VaxForm

CoV2-OGEN1

Protein Subunit

Yisheng Biopharma

PIKA COVID-19 Vaccine